Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Nuvectis Pharma (NVCT) Equity Ratio (2021 - 2026)

Nuvectis Pharma has reported Equity Ratio over the past 6 years, most recently at 0.56 for Q1 2026.

  • Quarterly results put Equity Ratio at 0.56 for Q1 2026, down 19.45% from a year ago — trailing twelve months through Mar 2026 was 0.56 (down 19.45% YoY), and the annual figure for FY2025 was 0.58, up 11.24%.
  • Equity Ratio reached 0.56 in Q1 2026 per NVCT's latest filing, down from 0.58 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.83 in Q1 2022 and bottomed at 0.52 in Q4 2024.
  • Median Equity Ratio over the past 5 years was 0.7 (2025), compared with a mean of 0.69.
  • The largest annual shift saw Equity Ratio soared 142.14% in 2022 before it fell 19.45% in 2026.
  • Over 5 years, Equity Ratio stood at 0.7 in 2022, then dropped by 8.74% to 0.64 in 2023, then fell by 17.92% to 0.52 in 2024, then grew by 11.24% to 0.58 in 2025, then decreased by 3.58% to 0.56 in 2026.
  • Business Quant data shows Equity Ratio for NVCT at 0.56 in Q1 2026, 0.58 in Q4 2025, and 0.67 in Q3 2025.